Venus Remedies Ltd

₹ 329 -1.94%

19 Apr - close price

venusremedies.com BSE: 526953 NSE : VENUSREM

About

Incorporated in 1989, Venus Remedies
Ltd is a research based pharmaceutical company and an injectable manufacturer^[1]

Key Points

Business Overview:^[1]^[2]
VSR is one of the largest manufacturers of meropenem antibiotics in India. It offers a wide range of pharmaceutical products that cater to various therapeutic areas, including anti infective (antibiotics), antimicrobial resistance, oncology, neurology, pain management, skin
& wound care. Company has 800+ marketing authorizations globally, 100+ patents and 90+ product basket which includes formulations such as injectables,
tablets, and topical preparations

Website BSE NSE

Market Cap ₹ 440 Cr.
Current Price ₹ 329
High / Low ₹ 430 / 186
Stock P/E 17.2
Book Value ₹ 365
Dividend Yield 0.00 %
ROCE 8.03 %
ROE 6.24 %
Face Value ₹ 10.0

Add ratio to table

Edit ratios

Pros

Company is almost debt free.
Stock is trading at 0.90 times its book value
Company has delivered good profit growth of 25.3% CAGR over last 5 years

Cons

Though the company is reporting repeated profits, it is not paying out dividend
Company has a low return on equity of 8.77% over last 3 years.
Debtor days have increased from 29.7 to 58.0 days.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations

Edit Columns

Loading peers table ...

Detailed Comparison with:

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

	Dec 2020	Mar 2021	Jun 2021	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023
	114.07	102.44	136.85	192.64	117.44	128.77	154.93	124.75	109.63	148.53	98.63	170.19	131.23
	101.03	94.57	117.50	164.71	103.21	121.46	136.68	109.58	102.55	127.50	85.16	157.06	118.23
Operating Profit	13.04	7.87	19.35	27.93	14.23	7.31	18.25	15.17	7.08	21.03	13.47	13.13	13.00
OPM %	11.43%	7.68%	14.14%	14.50%	12.12%	5.68%	11.78%	12.16%	6.46%	14.16%	13.66%	7.71%	9.91%
	5.62	23.92	1.92	2.97	1.07	2.47	1.41	1.77	3.75	3.24	2.06	2.93	2.42
Interest	1.73	0.87	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Depreciation	8.42	9.18	8.36	8.46	8.40	7.36	7.57	8.77	6.97	8.06	7.32	6.21	6.30
Profit before tax	8.51	21.74	12.91	22.44	6.90	2.42	12.09	8.17	3.86	16.21	8.21	9.85	9.12
Tax %	25.97%	-77.78%	-13.01%	-7.53%	-13.77%	0.00%	8.27%	5.39%	32.38%	53.49%	47.14%	44.67%	10.20%
	6.29	38.65	14.59	24.13	7.85	2.42	11.09	7.73	2.61	7.54	4.34	5.45	8.19
EPS in Rs	5.10	31.32	10.91	18.05	5.87	1.81	8.30	5.78	1.95	5.64	3.25	4.08	6.13
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2012	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	TTM
	397	452	515	443	392	375	355	299	316	511	574	534	549
	291	333	382	356	312	328	312	265	273	464	505	473	488
Operating Profit	106	118	133	87	80	47	44	34	43	47	69	62	61
OPM %	27%	26%	26%	20%	20%	13%	12%	11%	14%	9%	12%	12%	11%
	0	0	0	1	1	1	1	-4	-5	41	8	10	11
Interest	27	24	29	41	37	34	35	25	13	13	0	0	0
Depreciation	24	32	39	45	40	39	33	33	31	34	33	31	28
Profit before tax	55	63	66	2	3	-25	-23	-28	-6	41	45	40	43
Tax %	9%	9%	7%	-123%	60%	18%	-13%	4%	-31%	-32%	-10%	28%
	50	57	61	5	1	-20	-27	-27	-8	54	49	29	26
EPS in Rs	51.35	54.21	53.27	3.98	1.05	-16.40	-21.54	-21.97	-6.67	43.97	36.65	21.67	19.10
Dividend Payout %	6%	6%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%

Compounded Sales Growth
10 Years:	2%
5 Years:	9%
3 Years:	19%
TTM:	6%

Compounded Profit Growth
10 Years:	-7%
5 Years:	25%
3 Years:	184%
TTM:	7%

Stock Price CAGR
10 Years:	1%
5 Years:	57%
3 Years:	1%
1 Year:	60%

Return on Equity
10 Years:	3%
5 Years:	5%
3 Years:	9%
Last Year:	6%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2012	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Sep 2023
Equity Capital	10	11	11	11	11	12	12	12	12	12	13	13	13
Reserves	300	377	456	455	433	382	356	329	320	374	436	465	474
	220	271	288	319	327	308	302	294	216	48	39	39	39
	56	71	81	60	63	65	78	97	96	113	91	92	112
Total Liabilities	587	729	836	845	834	767	748	732	644	547	579	609	638
	336	381	416	426	434	389	370	347	271	244	225	200	189
CWIP	23	48	68	78	80	66	65	65	25	25	25	26	26
Investments	29	29	29	29	29	29	0	0	0	0	0	20	3
	199	272	323	312	291	283	314	320	348	277	329	363	421
Total Assets	587	729	836	845	834	767	748	732	644	547	579	609	638

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2012	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023
	38	51	53	67	42	62	52	44	78	132	41	28
	-94	-102	-94	-67	3	-18	-11	-11	-5	56	-17	-51
	56	55	39	-0	-46	-44	-40	-35	-72	-162	-9	0
Net Cash Flow	0	3	-2	-1	-0	0	0	-2	1	26	15	-23

Ratios

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2012	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023
Debtor Days	41	43	44	49	50	41	45	38	34	12	19	58
Inventory Days	155	175	173	189	210	230	242	283	282	130	121	123
Days Payable	20	25	34	35	36	50	48	67	70	74	48	53
Cash Conversion Cycle	176	193	183	203	223	220	239	254	246	67	93	129
Working Capital Days	91	104	118	149	180	164	143	130	171	68	84	118
ROCE %	17%	15%	13%	6%	5%	1%	2%	1%	3%	6%	10%	8%

Shareholding Pattern

Numbers in percentages

2 Recently

	Jun 2021	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024
	40.81%	40.81%	40.81%	40.81%	41.76%	41.76%	41.76%	41.76%	41.76%	41.76%	41.76%	41.76%
	0.02%	0.10%	0.28%	0.33%	0.96%	1.13%	1.07%	1.00%	0.98%	1.03%	1.59%	1.48%
	59.17%	59.09%	58.91%	58.86%	57.28%	57.11%	57.19%	57.26%	57.26%	57.21%	56.65%	56.76%
No. of Shareholders	14,419	16,617	18,231	19,952	21,189	22,015	22,243	21,719	20,498	19,267	19,560	19,913

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
	37.51%	37.51%	37.51%	35.89%	35.89%	40.81%	41.76%	41.76%
	0.48%	0.48%	0.04%	0.04%	0.04%	0.33%	1.00%	1.48%
	0.28%	0.45%	0.02%	0.00%	0.00%	0.00%	0.00%	0.00%
	61.73%	61.56%	62.43%	64.07%	64.07%	58.86%	57.26%	56.76%
No. of Shareholders	20,556	19,316	18,375	17,209	13,829	19,952	21,719	19,913

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Venus Remedies Ltd

Venus Remedies Ltd

Peer comparison

Quarterly Results

Profit & Loss

Balance Sheet

Cash Flows

Ratios

Shareholding Pattern

Documents

Announcements

Annual reports

Credit ratings